Connection

Alessandra Latini to Reverse Transcriptase Inhibitors

Back to Details
This is a "connection" page, showing publications Alessandra Latini has written about Reverse Transcriptase Inhibitors.
Alessandra Latini
Connection Strength
0.221
Reverse Transcriptase Inhibitors
  1. Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients. AIDS. 2017 01 28; 31(3):457-459.
    View in: PubMed
    Score: 0.144
  2. Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy. J Antimicrob Chemother. 2018 07 01; 73(7):1949-1954.
    View in: PubMed
    Score: 0.040
  3. Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial. J Antimicrob Chemother. 2017 07 01; 72(7):2055-2059.
    View in: PubMed
    Score: 0.037
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.